Oulu Mentalcare Oy

Running trials

• Recruiting

  NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT06963021· Phase 3· Source

• Recruiting

  Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT06966401· Phase 3· Source

• Active, not recruiting

  An Open-Label Study of Azetukalner in Major Depressive Disorder

  NCT06922110· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression2 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open- labeled Long-term Extension Treatment with Aticaprant

  2024-511557-21-00· Phase 3· Source

• Completed

  Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder

  NCT06029439· Phase 3· Source

• Completed

  Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder

  NCT06058039· Phase 3· Source